Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy

被引:205
作者
Trotman, RL
Williamson, JC
Shoemaker, DM
Salzer, WL
机构
[1] Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med, Infect Dis Sect, Winston Salem, NC 27157 USA
[2] Univ Missouri, Hlth Sci Ctr, Dept Internal Med, Div Infect Dis, Columbia, MO USA
关键词
D O I
10.1086/444500
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Continuous renal replacement therapy (CRRT) is now commonly used as a means of support for critically ill patients with renal failure. No recent comprehensive guidelines exist that provide antibiotic dosing recommendations for adult patients receiving CRRT. Doses used in intermittent hemodialysis cannot be directly applied to these patients, and antibiotic pharmacokinetics are different than those in patients with normal renal function. We reviewed the literature for studies involving the following antibiotics frequently used to treat critically ill adult patients receiving CRRT: vancomycin, linezolid, daptomycin, meropenem, imipenem-cilastatin, nafcillin, ampicillin-sulbactam, piperacillin-tazobactam, ticarcillin-clavulanic acid, cefazolin, cefotaxime, ceftriaxone, ceftazidime, cefepime, aztreonam, ciprofloxacin, levofloxacin, moxifloxacin, clindamycin, colistin, amikacin, gentamicin, tobramycin, fluconazole, itraconazole, voriconazole, amphotericin B (deoxycholate and lipid formulations), and acyclovir. We used these data, as well as clinical experience, to make recommendations for antibiotic dosing in critically ill patients receiving CRRT.
引用
收藏
页码:1159 / 1166
页数:8
相关论文
共 61 条
[21]   PHARMACODYNAMICS OF INTRAVENOUS CIPROFLOXACIN IN SERIOUSLY ILL-PATIENTS [J].
FORREST, A ;
NIX, DE ;
BALLOW, CH ;
GOSS, TF ;
BIRMINGHAM, MC ;
SCHENTAG, JJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (05) :1073-1081
[22]   Pharmacokinetics of moxifloxacin in patients undergoing continuous venovenous haemodiafiltration [J].
Fuhrmann, V ;
Schenk, P ;
Jaeger, W ;
Ahmed, S ;
Thalhammer, F .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 54 (04) :780-784
[23]   Pharmacokinetics of meropenem in intensive care unit patients receiving continuous veno-venous hemofiltration or hemodiafiltration [J].
Giles, LJ ;
Jennings, AC ;
Thomson, AH ;
Creed, G ;
Beale, RJ ;
McLuckie, A .
CRITICAL CARE MEDICINE, 2000, 28 (03) :632-637
[24]   Pharmacokinetics of levofloxacin during continuous veno-venous hemofiltration [J].
Hansen, E ;
Bucher, M ;
Jakob, W ;
Lemberger, P ;
Kees, F .
INTENSIVE CARE MEDICINE, 2001, 27 (02) :371-375
[25]  
HARDIN TC, 1994, PHARMACOTHERAPY, V14, P147
[26]   Pharmacokinetics of imipenem and cilastatin during continuous venovenous hemodialysis in patients who are critically ill [J].
Hashimoto, S ;
Honda, M ;
Yamaguchi, M ;
Sekimoto, M ;
Tanaka, Y .
ASAIO JOURNAL, 1997, 43 (01) :84-88
[27]  
Joos B, 1996, NEPHROL DIAL TRANSPL, V11, P1582
[28]   Determinants of vancomycin clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis [J].
Joy, MS ;
Matzke, GR ;
Frye, RF ;
Palevsky, PM .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 31 (06) :1019-1027
[29]   A primer on continuous renal replacement therapy for critically ill patients [J].
Joy, MS ;
Matzke, GR ;
Armstrong, DK ;
Marx, MA ;
Zarowitz, BJ .
ANNALS OF PHARMACOTHERAPY, 1998, 32 (03) :362-375
[30]  
Khajehdehi P, 2000, CLIN NEPHROL, V54, P351